Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate...

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Breast tumor kinase (Brk), also known as PTK6, is a nonreceptor tyrosine kinase.
• Aberrant Brk expression is linked to various cancers, promoting cell proliferation and transformation.
• Cancer-associated somatic mutations in the Brk gene have been identified, but their functional impact remains largely uncharacterized.

Purpose of the Study:

• To investigate the functional consequences of cancer-associated somatic mutations on Brk activity and signaling.
• To determine how specific mutations within regulatory domains affect Brk's autoinhibited conformation and substrate interactions.

Main Methods:

• Analysis of a panel of cancer-associated Brk mutations.
• Biochemical assays to assess Brk enzymatic activity.
• Examination of substrate recognition and phosphorylation patterns.

Main Results:

• Several Brk mutations were found to activate the kinase, while two mutations eliminated its enzymatic activity.
• Mutations L16F, R131L, and P450L, located in the SH3, SH2 domains, and C-terminal tail respectively, were shown to activate Brk.
• These activating mutations disrupt intramolecular interactions, releasing autoinhibition.
• Mutations exhibited differential effects on substrate recognition and phosphorylation, indicating varied impacts on downstream signaling.

Conclusions:

• Cancer-associated mutations can significantly modulate Brk activity, leading to either activation or inactivation.
• Specific mutations within regulatory domains can disrupt autoinhibition, promoting oncogenic signaling.
• The observed differential substrate effects suggest complex mechanisms by which Brk mutations influence cancer progression.